Efficacy of intramuscular diclofenac in the prevention of post-ERCP pancreatitis
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0001175
- Lead Sponsor
- Yeongnam University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1544
Subjects who agree to consent for the study
Intact major papilla
1) Unwillingness or inability to consent for the study
2) Procedure performed on major papilla previously
3) Standard contraindications to ERCP
4) ERCP for biliary stent removal or exchange without anticipated pancreatogram
5) Acute pancreatitis or acute exacerbation of chronic pancreatitis, elevatation of amylase or lipase level above three fold of upper normal limit within 72 hours
6) Underlying severe heart, lung or endocrine disorder
7) Severe abnormality in liver function
8) Hematologic disorder
9) Pregnancy or possibility of pregnancy
10) Received Non-Steroidal Anti-Inflammatory Drugs in prior 7 days (aspirin 325 mg or less OK)
11) Contraindication to Non-Steroidal Anti-Inflammatory Drugs (Renal failure (Cr > 1.4) or Active or recent gastrointestinal hemorrhage)
12) Allergy / hypersensitivity to aspirin or Non-Steroidal Anti-Inflammatory Drugs
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare incidence of post ERCP pancreatitis in each group
- Secondary Outcome Measures
Name Time Method Compare incidence of moderate to severe or severe pancreatitis;Compare side effect of drug in each group